9.69
price down icon4.25%   -0.43
after-market アフターアワーズ: 9.88 0.19 +1.96%
loading
前日終値:
$10.12
開ける:
$10.25
24時間の取引高:
1.16M
Relative Volume:
0.55
時価総額:
$620.36M
収益:
$170.44M
当期純損益:
$-193.88M
株価収益率:
-2.5812
EPS:
-3.7541
ネットキャッシュフロー:
$-126.38M
1週間 パフォーマンス:
-0.41%
1か月 パフォーマンス:
-19.12%
6か月 パフォーマンス:
-13.17%
1年 パフォーマンス:
+13.87%
1日の値動き範囲:
Value
$9.635
$10.38
1週間の範囲:
Value
$9.175
$10.51
52週間の値動き範囲:
Value
$5.455
$16.19

Regenxbio Inc Stock (RGNX) Company Profile

Name
名前
Regenxbio Inc
Name
セクター
Healthcare (1079)
Name
電話
240-552-8181
Name
住所
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
職員
371
Name
Twitter
@REGENXBIO
Name
次回の収益日
2026-08-06
Name
最新のSEC提出書
Name
RGNX's Discussions on Twitter

Compare RGNX vs VRTX, REGN, ARGX, RVMD, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
RGNX icon
RGNX
Regenxbio Inc
9.69 621.64M 170.44M -193.88M -126.38M -3.7541
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
477.10 121.57B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
762.63 69.95B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
853.82 55.61B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
187.53 39.98B 742.00K -1.37B -1.07B -7.0731
ONC icon
ONC
Beone Medicines Ltd Adr
316.01 33.81B 5.76B 514.49M 1.10B 4.4813

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-28 再開されました Barclays Overweight
2025-02-11 ダウングレード Goldman Buy → Neutral
2025-02-07 再開されました Raymond James Outperform
2024-11-15 再開されました Morgan Stanley Overweight
2024-10-10 再開されました Raymond James Outperform
2024-06-07 開始されました Goldman Buy
2024-03-11 開始されました H.C. Wainwright Buy
2024-03-08 アップグレード RBC Capital Mkts Sector Perform → Outperform
2024-03-06 アップグレード Leerink Partners Market Perform → Outperform
2024-02-21 再開されました Raymond James Outperform
2023-11-01 開始されました Stifel Buy
2023-06-02 開始されました Robert W. Baird Outperform
2022-06-23 開始されました Berenberg Buy
2021-12-15 開始されました Wedbush Neutral
2021-10-19 再開されました Morgan Stanley Overweight
2021-01-06 アップグレード Raymond James Outperform → Strong Buy
2020-12-16 開始されました UBS Buy
2020-06-25 再開されました BofA/Merrill Buy
2020-05-13 開始されました RBC Capital Mkts Sector Perform
2019-08-20 アップグレード SVB Leerink Underperform → Mkt Perform
2019-06-18 繰り返されました Chardan Capital Markets Buy
2019-06-14 再開されました Raymond James Outperform
2019-06-05 繰り返されました Chardan Capital Markets Buy
2019-02-25 アップグレード Evercore ISI In-line → Outperform
2019-02-05 アップグレード Raymond James Outperform → Strong Buy
2018-12-17 繰り返されました Chardan Capital Markets Buy
2018-11-08 繰り返されました BofA/Merrill Neutral
2018-08-08 繰り返されました Chardan Capital Markets Buy
2018-07-23 ダウングレード BofA/Merrill Buy → Neutral
2018-07-10 繰り返されました Chardan Capital Markets Buy
2018-05-09 繰り返されました Barclays Overweight
2018-04-09 繰り返されました Chardan Capital Markets Buy
2018-03-12 ダウングレード Evercore ISI Outperform → In-line
2018-02-13 開始されました Mizuho Neutral
2017-11-09 再開されました Morgan Stanley Overweight
すべてを表示

Regenxbio Inc (RGNX) 最新ニュース

pulisher
Jul 27, 2026

Diluted shares outstanding of REGENXBIO, Inc. – HAM:RB0 - TradingView

Jul 27, 2026
pulisher
Jul 27, 2026

Regenxbio Inc (RGNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Price to book ratio of REGENXBIO, Inc. – HAM:RB0 - TradingView

Jul 27, 2026
pulisher
Jul 27, 2026

Inventory turnover of REGENXBIO, Inc. – HAM:RB0 - TradingView

Jul 27, 2026
pulisher
Jul 27, 2026

Regenxbio Inc (RGNX) Cash Flow - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Regenxbio Inc (RGNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jul 27, 2026
pulisher
Jul 26, 2026

Regenxbio Inc (RGNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

RGNX|Regenxbio Inc|Price:9.730|Chg%:-0.520 - TradingKey

Jul 26, 2026
pulisher
Jul 25, 2026

FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy - Stocktwits

Jul 25, 2026
pulisher
Jul 25, 2026

Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits

Jul 25, 2026
pulisher
Jul 24, 2026

RGNX Stock Slumps 15% After-Hours — What’s Driving The Selloff? - Stocktwits

Jul 24, 2026
pulisher
Jul 24, 2026

REGENXBIO Inc. (RGNX) stock price, news, quote and history - Yahoo Finance Australia

Jul 24, 2026
pulisher
Jul 24, 2026

REGENXBIO Inc. Revenue Breakdown – NASDAQ:RGNX - TradingView

Jul 24, 2026
pulisher
Jul 24, 2026

Regenxbio Inc (RGNX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 24, 2026
pulisher
Jul 23, 2026

Matt Wilsey Built a Gene Therapy for His Daughter. He Says the FDA Isn't Ready for What Comes Next. - finance.biggo.com

Jul 23, 2026
pulisher
Jul 23, 2026

REGENXBIO Inc. (RGNX) Stock Price, News, Quote & History - Yahoo! Finance Canada

Jul 23, 2026
pulisher
Jul 21, 2026

Lawsuit alleges Regenxbio misled investors on g... - Pluang

Jul 21, 2026
pulisher
Jul 21, 2026

Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm - Morningstar

Jul 21, 2026
pulisher
Jul 21, 2026

RegenXBio Raises Capital Through Public Equity Offering - The Globe and Mail

Jul 21, 2026
pulisher
Jul 20, 2026

(RGNX) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Jul 20, 2026
pulisher
Jul 20, 2026

Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments - Benzinga

Jul 20, 2026
pulisher
Jul 20, 2026

REGENXBIO Raises $100 Million in Public Offering of Common Stock and Pre-Funded Warrants - Minichart

Jul 20, 2026
pulisher
Jul 20, 2026

REGENXBIO (NASDAQ: RGNX) prices stock and warrant sale, netting $107.8M - Stock Titan

Jul 20, 2026
pulisher
Jul 20, 2026

Regenxbio prices expected $100M public offering - The Pharma Letter

Jul 20, 2026
pulisher
Jul 20, 2026

Regenxbio (RGNX) Reports Positive Long-Term Results for Gene The - GuruFocus

Jul 20, 2026
pulisher
Jul 20, 2026

Frontier tech research, news & data - MLQ.ai

Jul 20, 2026
pulisher
Jul 19, 2026

Regenxbio (RGNX) Reports Positive Long-Term Results for Gene Therapy in Eye Conditions - GuruFocus

Jul 19, 2026
pulisher
Jul 18, 2026

Regenxbio reports 5-year wet AMD efficacy data for sura-vec gene therapy at ASRS meeting - Bitget

Jul 18, 2026
pulisher
Jul 18, 2026

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting - PR Newswire

Jul 18, 2026
pulisher
Jul 18, 2026

RGNX Stock Sinks After $100M Equity Deal Hits Sentiment - timothysykes.com

Jul 18, 2026
pulisher
Jul 18, 2026

REGENXBIO Stock Slides After $100M Equity Offering Pricing - timothysykes.com

Jul 18, 2026
pulisher
Jul 18, 2026

REGENXBIO Stock Slides After $100M Equity Offering Shock - StocksToTrade

Jul 18, 2026
pulisher
Jul 18, 2026

Form 424B5 Regenxbio Inc For: 17 July By Investing.com - Investing.com Australia

Jul 18, 2026
pulisher
Jul 18, 2026

Regenxbio prices $100m public offering at $9 per share By Investing.com - Investing.com South Africa

Jul 18, 2026
pulisher
Jul 18, 2026

Form 424B5 Regenxbio Inc For: 17 July - Investing.com UK

Jul 18, 2026
pulisher
Jul 18, 2026

REGENXBIO (RGNX) Launches $100M Public Offering at $9.00 per Sha - GuruFocus

Jul 18, 2026
pulisher
Jul 17, 2026

REGENXBIO stock dips on $100M equity offering - MSN

Jul 17, 2026
pulisher
Jul 17, 2026

Regenxbio Shares Fall on $100M Stock, Pre-Funded Warrant Offering - Moomoo

Jul 17, 2026
pulisher
Jul 17, 2026

REGENXBIO (NASDAQ: RGNX) launches $100M equity and pre-funded warrant raise - Stock Titan

Jul 17, 2026
pulisher
Jul 17, 2026

Regenxbio (RGNX) Launches $100 Million Public Offering - GuruFocus

Jul 17, 2026
pulisher
Jul 17, 2026

RGNX Stock Slides As $100M Offering And Legal Heat Hit - StocksToTrade

Jul 17, 2026
pulisher
Jul 17, 2026

REGENXBIO Prices $100 Million Public Offering - Moomoo

Jul 17, 2026
pulisher
Jul 17, 2026

Crude Oil Surges 4%; Travelers Posts Upbeat Q2 results - Benzinga

Jul 17, 2026
pulisher
Jul 17, 2026

RGNX Stock Dips As Equity Offering And Litigation Raise Risk - timothysykes.com

Jul 17, 2026
pulisher
Jul 17, 2026

REGENXBIO raises USD 100m amid pivotal year for gene therapy pipeline - AllSci

Jul 17, 2026
pulisher
Jul 17, 2026

REGENXBIO files prospectus for up to $100M common stock offering - MSN

Jul 17, 2026
pulisher
Jul 17, 2026

Gene Therapy Pioneer REGENXBIO Prices Public Offering, Aims to Raise $100 Million - finance.biggo.com

Jul 17, 2026
pulisher
Jul 17, 2026

Regenxbio prices $100m public offering at $9 per share - Investing.com

Jul 17, 2026
pulisher
Jul 17, 2026

REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants - PR Newswire

Jul 17, 2026
pulisher
Jul 17, 2026

Why is Regenxbio stock falling sharply today? - Investing.com

Jul 17, 2026

Regenxbio Inc (RGNX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Regenxbio Inc (RGNX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
PAKOLA STEVE
Chief Medical Officer
Jul 02 '26
Sale
13.64
2,161
29,476
213,009
PAKOLA STEVE
Chief Medical Officer
Jul 01 '26
Option Exercise
7.86
36,725
288,658
249,734
PAKOLA STEVE
Chief Medical Officer
Jul 01 '26
Sale
12.86
36,725
472,284
213,009
PAKOLA STEVE
Chief Medical Officer
Jun 29 '26
Sale
11.04
19,608
216,472
213,009
$90.58
price down icon 2.44%
$119.52
price down icon 2.82%
$33.91
price down icon 1.77%
$58.43
price down icon 1.00%
$205.52
price up icon 0.02%
ONC ONC
$316.01
price down icon 1.88%
大文字化:     |  ボリューム (24 時間):